Return
A tumor microenvironment-responsive calcium overload nanoplatform inducing PANoptosis for enhanced cancer immunotherapy
A
Y
Y
Y
C
L
J
DOI:10.1016/j.mtbio.2026.103514.png)
Abstract
En 中文
PANoptosis, a newly characterized form of inflammatory programmed cell death that integrates multiple cell death modalities, offers distinct advantages in both potent tumor cell killing and activation of antitumor immunity. However, strategies that can effectively induce PANoptosis in tumor cells remain scarce. Herein, we constructed a tumor microenvironment-responsive nanoplatform (HA-MnO2-FTY720@CaO2, HMFC) comprising a CaO2 core and a MnO2 shell, loaded with fingolimod (FTY720) and surface-functionalized with hyaluronic acid (HA) for CD44-mediated targeting. Under the mildly acidic and glutathione (GSH)-rich conditions of the tumor microenvironment (TME), the MnO2 shell degrades, liberating FTY720 and exposing the CaO2 core. The CaO2 subsequently decomposes to release Ca2+ and H2O2. FTY720 inhibits Transient Receptor Potential Melastatin 7 (TRPM7) channels, disrupting Ca2+/Mg2+ homeostasis and thereby provoking severe calcium overload. Simultaneously, MnO2 depletes GSH and, together with CaO2-derived H2O2, promotes a Fenton-like reaction that generates abundant reactive oxygen species (ROS), thereby disrupting intracellular redox homeostasis. In addition, Mn2+ released from MnO2 degradation activates the cGAS–STING pathway, further contributing to DC maturation and antitumor immunity. This orchestrated immune response markedly suppresses tumor growth and when combined with anti-PD-L1 therapy, induces a pronounced abscopal effect. Together, our results indicate that calcium overload, FTY720-mediated TRPM7 inhibition, and MnO2-induced redox imbalance can drive PANoptosis, offering a new concept for enhancing cancer immunotherapy.
Keywords:
Calcium overload
Reactive oxygen species
PANoptosis
Immunogenic cell death
Tumor microenvironment-responsive nanoplatform
Journal
IF:
10.2
Papers:
3.6K
Citations:
9.5K
